#Soberana02💉es ya el primer candidato vacunal latinoamericano en fase III. Abdala se le unirá próximamente.
Junto a estos logros, la ciencia cubana presenta Soberana 01A, destinada a convalecientes de #COVID19.
Los 5 candidatos brindarán salud y seguridad a Cuba 🇨🇺 y el mundo. pic.twitter.com/FkzD4BdXV7
— Bruno Rodríguez P (@BrunoRguezP) March 4, 2021
In statements to Prensa Latina, Research Director at the Finlay Vaccine Institute (IFV) Dagmar Garcia pointed out that this product was part of the five formulations corresponding to Soberana 01, first presented by Cuba to face the pandemic.
With Soberana Plus, a study was carried out in convalescent COVID-19 patients between 19 and 59, who had mild symptoms or were asymptomatic for COVID-19 but had tested positive.
The study showed the ability of the molecule to stimulate protective levels of neutralizing antibodies and protect patients against possible reinfection.
Given these results, IFV Director Vicente Verez stressed that this step is essential in the protection against COVID-19, and when the mass vaccination stage is reached, it will help to face SARS-CoV-2 variants, mutations and strains.
(Taken from Prensa Latina)